Kaos Capital Demands Board Shakeup at Capricor Therapeutics

The activist investor, led by CEO Adam Arviv, argues that Capricor is currently overexposed, relying too heavily on its lead program, deramiocel, while burning through capital at an unsustainable rate. Financial filings for the first half of 2026 reveal that the company’s operating expenses hit $79.7 million, with general and administrative costs doubling to $23.5 million compared to the previous year. Kaos Capital contends that these figures necessitate a rigorous cash preservation plan and a top-to-bottom review of discretionary spending.

Beyond fiscal tightening, Kaos Capital is pushing for the creation of an M&A and Strategic Alternatives Committee, to be chaired by a shareholder-backed director. The firm envisions transforming Capricor from a single-asset bet into a broader biotechnology platform by acquiring or partnering on complementary technologies in fields like inflammation and regenerative medicine. Furthermore, the investor is calling for a professional resolution to the company’s ongoing legal issues, which have included multiple shareholder lawsuits and derivative actions. Should the board fail to engage within the requested fifteen-business-day window, Kaos Capital has signaled its intent to pursue a full-scale campaign to replace directors and potentially overhaul senior management.